Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists

Yoshio Ogino; Norikazu Ohtake; Yoshikazu Nagae; Kenji Matsuda; Makoto Ishikawa; Minoru Moriya; Maki Kanesaka; Yuko Mitobe; Junko Ito; Tetsuya Kanno; Akane Ishihara; Hisashi Iwaasa; Tomoyuki Ohe; Akio Kanatani; Takehiro Fukami

doi:10.1016/j.bmcl.2008.08.021

Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists

Yoshio Ogino, Norikazu Ohtake, Yoshikazu Nagae, Kenji Matsuda, Makoto Ishikawa, Minoru Moriya, Maki Kanesaka, Yuko Mitobe, Junko Ito, Tetsuya Kanno, Akane Ishihara, Hisashi Iwaasa, Tomoyuki Ohe, Akio Kanatani, Takehiro Fukami

研究成果: Article › 査読

18 被引用数 (Scopus)

抄録

Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5- and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl)benzimidazole (2r: IC₅₀ = 3.3 nM) and 5-(2-methyltetrazol-5-yl)benzimidazole (2u: IC₅₀ = 5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists. Crown

本文言語	English
ページ（範囲）	4997-5001
ページ数	5
ジャーナル	Bioorganic and Medicinal Chemistry Letters
巻	18
号	18
DOI	https://doi.org/10.1016/j.bmcl.2008.08.021
出版ステータス	Published - 2008 9月 15
外部発表	はい

ASJC Scopus subject areas

生化学
分子医療
分子生物学
薬科学
創薬
臨床生化学
有機化学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.bmcl.2008.08.021

他のファイルとリンク

フィンガープリント

「Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Ogino, Y., Ohtake, N., Nagae, Y., Matsuda, K., Ishikawa, M., Moriya, M., Kanesaka, M., Mitobe, Y., Ito, J., Kanno, T., Ishihara, A., Iwaasa, H., Ohe, T., Kanatani, A., & Fukami, T. (2008). Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 18(18), 4997-5001. https://doi.org/10.1016/j.bmcl.2008.08.021

Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists. / Ogino, Yoshio; Ohtake, Norikazu; Nagae, Yoshikazu その他.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 18, No. 18, 15.09.2008, p. 4997-5001.

研究成果: Article › 査読

Ogino, Y, Ohtake, N, Nagae, Y, Matsuda, K, Ishikawa, M, Moriya, M, Kanesaka, M, Mitobe, Y, Ito, J, Kanno, T, Ishihara, A, Iwaasa, H, Ohe, T, Kanatani, A & Fukami, T 2008, 'Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists', Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 18, pp. 4997-5001. https://doi.org/10.1016/j.bmcl.2008.08.021

@article{175cad71526a40b682ee44f724ea83ba,

title = "Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists",

abstract = "Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5- and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl)benzimidazole (2r: IC50 = 3.3 nM) and 5-(2-methyltetrazol-5-yl)benzimidazole (2u: IC50 = 5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists. Crown",

keywords = "Antagonist, Anti-obesity, Benzimidazole, Neuropeptide Y, Y5 receptor",

author = "Yoshio Ogino and Norikazu Ohtake and Yoshikazu Nagae and Kenji Matsuda and Makoto Ishikawa and Minoru Moriya and Maki Kanesaka and Yuko Mitobe and Junko Ito and Tetsuya Kanno and Akane Ishihara and Hisashi Iwaasa and Tomoyuki Ohe and Akio Kanatani and Takehiro Fukami",

year = "2008",

month = sep,

day = "15",

doi = "10.1016/j.bmcl.2008.08.021",

language = "English",

volume = "18",

pages = "4997--5001",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Limited",

number = "18",

}

TY - JOUR

T1 - Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists

AU - Ogino, Yoshio

AU - Ohtake, Norikazu

AU - Nagae, Yoshikazu

AU - Matsuda, Kenji

AU - Ishikawa, Makoto

AU - Moriya, Minoru

AU - Kanesaka, Maki

AU - Mitobe, Yuko

AU - Ito, Junko

AU - Kanno, Tetsuya

AU - Ishihara, Akane

AU - Iwaasa, Hisashi

AU - Ohe, Tomoyuki

AU - Kanatani, Akio

AU - Fukami, Takehiro

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5- and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl)benzimidazole (2r: IC50 = 3.3 nM) and 5-(2-methyltetrazol-5-yl)benzimidazole (2u: IC50 = 5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists. Crown

AB - Syntheses and structure-activity relationships of a novel class of 2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists are described. Optimization of the lead compound 2a by incorporating substituents into the 5-position or into both the 5- and 6-positions of the benzimidazole core part led to the identification of 5-(5-methyl-1,2,4-oxadiazol-2-yl)benzimidazole (2r: IC50 = 3.3 nM) and 5-(2-methyltetrazol-5-yl)benzimidazole (2u: IC50 = 5.9 nM), both of which are potent, selective, and orally bioavailable Y5 receptor antagonists. Crown

KW - Antagonist

KW - Anti-obesity

KW - Benzimidazole

KW - Neuropeptide Y

KW - Y5 receptor

UR - http://www.scopus.com/inward/record.url?scp=51349130429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349130429&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2008.08.021

DO - 10.1016/j.bmcl.2008.08.021

M3 - Article

C2 - 18752943

AN - SCOPUS:51349130429

VL - 18

SP - 4997

EP - 5001

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 18

ER -